
Overview
Join. Train. Respond.	Response Resources	Law and Strategy
National Disaster Medical System	Cybersecurity	Public Health Emergency Declarations
Medical Reserve Corps	At-Risk Individuals	Section 1135 Waivers
ESAR-VHP	Disaster Behavioral Health	National Response Framework and Emergency Support Function 8
	Emergency Prescription Assistance Program	Legal Authorities, Policies, and Strategies
	National Emergency Telemedicine Network
	ASPR TRACIE


Overview
Health Care Readiness	Programs and Activities	Resources and Funding	Related Programs
Stories from the Field	Hospital Preparedness Program	Health Care Readiness Funding	Critical Infrastructure Protection
Health Care Readiness Near You	Regional Disaster Health Response System	COVID-19 Health Care Preparedness and Response	Health and Social Services Recovery
	National Special Pathogen System	Health Care Readiness Program Webinars
	Workforce Capacity and Capability	Performance Measures, Guidance, and Reports


Overview
Medical Countermeasures	Biodefense
Project NextGen	Industrial Base Expansion
BARDA	S3: Science, Safety, and Security
Doing Business with BARDA	Strategic Planning and Committees
Strategic National Stockpile	Legal Authorities, Policies, and Strategies


Overview
Partnership Opportunities	Professional Resources	Join Us
Medical Countermeasures TechWatch	ASPR TRACIE	National Disaster Medical System
EZ-BAA: BARDA DRIVe Easy Broad Agency Announcement	National Emerging Special Pathogens Training and Education Center	Medical Reserve Corps
BARDA Broad Agency Announcement	Critical Infrastructure Protection	ESAR-VHP
IBx Connect	Boards and Committees
Blue Knight	NACCD - Children and Disasters
CARB-X	NACIDD - Disabilities and Disasters
BARDA Ventures	NACSD - Seniors and Disasters
BARDA DRIVe Accelerator Network	NBSB – Biodefense
Project BioShield
Find Us On SAM
ASPR Grant Opportunities


Overview
Technical Assistance and Information Management	GIS-Based Tools
ASPR TRACIE	HHS emPOWER Program
Regional Emergency Coordinators	GeoHEALTH
ASPR Ready	COVID-19 Test to Treat Locator
Training	COVID-19 Therapeutics Locator
HHS emPOWER Program Web-Based Training	Threat-specific Tools
Strategic National Stockpile Course Listing	CHEMM: Chemical Hazards Emergency Medical Management
Addressing the Needs of Older Adults in Disasters Web Based Training	REMM: Radiation Emergency Medical Management
Access and Functional Needs Web-Based Training
Risk Assessment Tools
Risk Identification and Site Criticality (RISC 2.0)


ASPR COVID-19 Response
For Health Care Professionals
For Patients
Test to Treat

NAVIGATION

Commercialization of COVID-19 Medical Countermeasures

Frequently Asked Questions

Commercialization is the transition of COVID-19 medical countermeasures, including vaccines, treatments, and test kits previously purchased by the U.S. Government (USG), to established pathways of procurement, distribution, and payment by both public and private payers.
Providing medical countermeasures in the commercial market is something that manufacturers, logistics companies, and payors do every day.

While there are many considerations and timelines may shift based on the trajectory of the virus, we anticipate that the transition of vaccines to more traditional pathways for procurement, distribution, and payment will occur in early fall.
Some of those considerations include what will be authorized and recommended by FDA and CDC, and what will align with a strain change for potential variants.
Provided that one is authorized and recommended by FDA and CDC, we expect this transition will align with a possible strain change that accounts for any potential variants.
The treatments transition to commercial markets will vary by product and will likely occur for at least one product before the end of the year.
The USG is working on determining the exact dates for COVID-19 vaccines and therapeutics. We will share more information about timelines when we are able.

The PHE does not affect the transition of vaccines and treatments to commercial markets.
In February 2023, HHS Secretary Becerra renewed the PHE for one last 90-day period planned to end at the end of the day on May 11, 2023. This action is based on the most recent COVID-19 trends and is consistent with the Administration statement on January 30, 2023, that the PHE is planned to end at the end of the day on May 11.
In the past, HHS has committed to providing 60 days-notice in advance of ending the PHE. To foster a smooth transition, HHS has given 90 days-notice instead.
Even with the planned end of the PHE at the end of the day on May 11, on May 12, all vaccines and treatments purchased by the U.S. government will continue to be distributed and available for free to U.S. residents. The PHE itself does not affect the supply or distribution of our vaccines or treatments. It also does not affect FDA’s ability to authorize various products, including tests, treatments, or vaccines for emergency use.

COVID-19 remains a significant public health priority for the Administration and for HHS. We know so many are still affected by COVID-19, particularly seniors and people with disabilities. We remain committed to maximizing availability of COVID-19 vaccines and treatments.
Our intention is that vaccines and treatments will remain available from all of the places U.S. residents currently receive them, whether it’s at their pharmacy or their health care provider.
Vaccines will remain free for most U.S. residents through the Vaccines for Children Program, Children’s Health Insurance Program, most commercial insurance, Medicare, and Medicaid programs.
Those with Medicare, Medicaid, and most private insurance will be able to access covered treatments, potentially with cost-sharing.

CDC’s Vaccines for Children Program will provide coverage for uninsured children as it does for other routine vaccinations.
HHS is actively working with vaccine and treatment manufacturers to ensure that Patient Assistance Programs that provide free access to these products are easy to use and broadly accessible.
HHS continues to invest in health systems and programs that support vaccine access and outreach in underserved communities – such as Federally Qualified Health Centers, Rural Health Clinics, and state and local health departments. These networks can be leveraged for access to COVID-19 vaccines and therapeutics as well as other needed medicines.